FOLFIRI(®) and Bevacizumab in first-line treatment for colorectal cancer patients: safety, efficacy and genetic polymorphisms

BACKGROUND: Over 50% of colorectal cancer (CRC) patients develop metastases. The aim of this study was to evaluate efficacy and tolerance of first-line FOLFIRI® + bevacizumab (B) treatment for metastatic CRC, and to assess genetic polymorphisms as potential markers. METHODS: Adult patients with hist...

Descripción completa

Detalles Bibliográficos
Autores principales: Bécouarn, Yves, Cany, Laurent, Pulido, Marina, Beyssac, Richard, Texereau, Patrick, Le Morvan, Valérie, Béchade, Dominique, Brunet, René, Aitouferoukh, Sofiane, Lalet, Caroline, Mathoulin-Pélissier, Simone, Fonck, Marianne, Robert, Jacques
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2014
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4022139/
https://www.ncbi.nlm.nih.gov/pubmed/24758527
http://dx.doi.org/10.1186/1756-0500-7-260

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4022139/
https://www.ncbi.nlm.nih.gov/pubmed/24758527
http://dx.doi.org/10.1186/1756-0500-7-260

Ejemplares similares